$1 Billion Investment in R&D and Manufacturing Expansion

The global investment is intended to fuel innovation of digitally-enabled therapies designed to enhance patient access to care, and their experience and outcomes. 

Through the development of digitally-enabled dialysis and critical care products and services, we aim to enable earlier and better-informed clinical decision-making, minimise disruption of care for patients and clinical teams, shift kidney care management from episodic to proactive, and enhance patient-care team connectivity.

We know that your time and resources are increasingly stretched, and clinicians urgently need smarter, scalable, and more sustainable care tools that can address more patients, more effectively while keeping pace with clinical complexity. 

As we use this investment to transform vital organ therapies, we’re focused on areas that will make a significant impact for you and your patients. We’re always guided by what you have told us is important to you.

We’ve been pleased to share innovations and production changes that have had significant positive impact for Australia and New Zealand.

Our innovation in MyPD continues, with the latest enhancements improving patient ability to send medically-relevant photographs to their clinic. We are committed to enhancing our remote patient management solution, knowing the positive impact it has on patient outcomes, proactive patient care and resource utilisation.  And with MyPD, these benefits are available for all PD patients – APD and CAPD.

We are proud to deliver advanced lifesaving critical care therapy with systems capable of continuous renal replacement therapy (CRRT) as well as multi-organ support, such as our PrisMax System. Beyond this, we continue to pursue novel diagnostic and therapeutic options for organ failure, including new approaches to sepsis management and to lung and liver function support.

We have already taken advantage of changing the source of our peritoneal dialysis fluids. Our PD fluids are now produced in a dedicated Vantive PD production facility, in Singapore. Sourcing fluids from this location has provided stable fluid supply for patients, from a location with a culture of innovation through process improvements, automation and digitalisation.

The production site has extensive available production capacity, ensuring that the growing demands for PD fluids can be serviced now, and in the future.

Over the last seven decades as Baxter, we have built a legacy of exceptional kidney care products and services. Now we are deepening our commitment to elevating the dialysis experience through digital solutions while evolving our organ support therapies to go beyond kidney care.

Our investment in R&D and production capacity will enable us to further improve the lives of patients, with better therapy access, care experience and outcomes.

We look forward to sharing the impact that this investment will have on you and your patients.